Track 5: Patient Engagement
This track, composed of 12 sessions, is themed, Operationalizing Patient Engagement, and Concepts of Meaningful Patient Engagement. It will address meaningful patient engagement in medical product development, from early product development, and approval, through maintenance phases. It focuses on important questions for all stakeholders, including:
- How do we meaningfully engage patients and incorporate their voices into decision-making throughout the medical product life cycle?
- How do we become truly patient- (and people-) centric in our approach?
- How do we operationalize patient-centric approaches in our day-to-day work?
- How can we measure the effectiveness of our efforts, both for patient outcomes and to meet the needs of other stakeholders such as industry and regulatory decision-makers?
- What have we learned that can be used to drive more meaningful patient engagement?
- How do stakeholders best work together to leverage their collective power and expertise to promote meaningful involvement of patients?
DIA 2018 is now Patients Included! Click here to learn more!
Sessions in Patient Engagement
Sunday, June 24 | Short Courses
Monday, June 25
- Patient-Focused Medicines Development: Where it has Led us to Today, What Challenges Remain, and What do we Still Need to do to Achieve Success?
- A Hot Debate: Perspectives on Benefit-Risk from Patients Across Diseases
- A New Ecosystem: The Nature of Relationships Between Patient Advocacy Groups and Sponsors
Tuesday, June 26
- Incorporating Patient Input Into US Food and Drug Administration’s Medical Product Development and Regulatory Decision
- The Patient's Assessment of the Patient-Focused Drug Development Meeting Initiatives
- Reaching the Underserved: Methods to Ensure Diversity and Inclusion for Patient Research, Clinical Trials, and Advisory Panels
- Using Advocacy Partnerships to Improve Real World Evidence in Clinical Trials
Global Perspectives on Patient Engagement
Wednesday, June 27
- Maintaining Patient Engagement in the Development of Patient-Reported Outcome (PRO) Measures
- How do Patients and Other Multi-Disciplinary Stakeholders Collaborate to Develop Patient Registries That Accelerate Research?
- Addressing the Elephant in the Room: A Hard Look at Metrics, Legal, Payers, and Other Leading Obstacles Facing the Sustainability of Patient Engagement
- Engaging the Rare Disease Community to Design Clinical Trials
- Patient Observation Versus Patient Engagement: Optimizing Development
Thursday, June 28
Who is This Track Designed For?
Professionals involved in: patient affairs, patient advocacy, patient groups, patient support services, medical affairs (including CMOs and MSLs), clinical trial design and optimization, clinical research and operations, regulatory affairs, regulatory agency, corporate and government affairs, safety and pharmacovigilance, outcomes research, epidemiology, and Health Technology Assessment..